文献速递妇科生殖医学

保留生育功能治疗浆液性交界性卵巢肿瘤伴卵巢外浸润性种植:MITO14研究数据库分析

Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
PubMed 文献 · Gynecol Oncol · 2022-02-26

MITO14多机构回顾性研究纳入13例FIGO2014 II-III期浆液性交界性卵巢肿瘤伴浸润性种植且接受保留生育功能手术的患者,中位随访146个月,11例(84.6%)复发,5例尝试妊娠中3例妊娠、2例分娩健康子代,观察结束时全部存活无病。

要点

  • 13例浆液性交界性卵巢肿瘤伴浸润性种植患者接受保留生育功能手术,中位随访146个月。
  • 11例(84.6%)至少一次复发,中位首次复发时间17个月,均接受二次手术(7例再次保留生育功能)。
  • 5例尝试妊娠者中3例至少一次妊娠、2例至少分娩一健康子代,观察结束时全部存活无病。

核心结论

  • 作者认为,在浆液性交界性卵巢肿瘤伴浸润性种植的情况下应考虑保留生育功能治疗。
  • 尽管复发率高,保留生育功能手术提供良好的生殖成功机会且对总生存无负面影响。

研究设计与样本

  • MITO14为多机构回顾性研究,系统收集连续浆液性交界性卵巢肿瘤患者数据。
  • 本分析纳入2002年8月至2019年5月间登记的13例FIGO2014 II-III期浆液性交界性卵巢肿瘤伴浸润性种植且接受保留生育功能手术的患者。
  • 排除年龄>45岁及需治疗的第二肿瘤干扰交界性卵巢肿瘤治疗者。
  • 主要终点为复发率和死亡率,次要终点为妊娠率和活产率。

主要发现

  • 自初次肿瘤细胞减灭术中位随访146个月(范围27-213个月)。
  • 11例(84.6%)至少一次复发,中位首次复发时间17个月(范围4-190个月),全部接受二次手术,其中7例再次保留生育功能手术。
  • 5例尝试妊娠,3例至少一次妊娠,2例至少分娩一健康子代。
  • 观察结束时全部患者存活无病。

临床怎么用

  • 作者认为,在浆液性交界性卵巢肿瘤伴浸润性种植的情况下应考虑保留生育功能治疗。
  • 作者指出,尽管复发率高,保留生育功能手术提供良好生殖成功机会且对总生存无负面影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Only 10-15% of serous borderline ovarian tumors (BOTs) with extra-ovarian disease have invasive implants, and conservative treatments have been rarely reported. The MITO14 is a multi-institutional retrospective study conducted with the aim of systematically collecting data from consecutive BOT patients. The present analysis reports the oncological and reproductive outcomes of women with serous BOT and invasive implants registered into the MITO14 database and conservatively treated between August 2002 and May 2019. METHODS: Thirteen patients (FIGO2014 stage II-III serous BOT with invasive implants) were recruited. Primary and secondary endpoints were, respectively, recurrence and death rates, and pregnancy and live birth rates. Only patients undergoing fertility-sparing surgery (FSS) were included, while patients were excluded in case of: age > 45 years; second tumor(s) requiring therapy interfering with the treatment of BOT. RESULTS: Median follow-up time from primary cytoreduction was 146 months (range 27-213 months). Eleven patients (84.6%) experienced at least one recurrence (median time to first relapse 17 months, range 4-190 months), all of these undergoing secondary surgery (FSS in 7). Five patients attempted to conceive: 3 achieved at least one pregnancy and 2 gave birth at least to a healthy child. At the end of the observation period, all patients were alive with no evidence of disease. CONCLUSIONS: Fertility-sparing treatment should be considered in a context of serous BOT with invasive implants. Despite the high rate of recurrence, FSS provides good chances of reproductive success without a negative impact on overall survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Falcone F, Malzoni M, Carnelli M, et al. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database. Gynecol Oncol. 2022. PMID: 35232587. doi:10.1016/j.ygyno.2022.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。